Rohit R. Arora, MD, FACC, FAHA, FACP, FSCAI Professor of Medicine Professor of Physiology and Biophysics Chairman of Cardiology Vice Chairman of Medicine Associate Chairman of Medicine for Research The Chicago Medical School Chicago, IL Joseph L. Blackshear, MD Professor of Medicine Department of Cardiology Mayo Clinic Jacksonville, FL
Francis Marchlinski, MD Professor of Medicine Director, Cardiac Electrophysiology University of Pennsylvania Health System Cardiovascular Medicine Division Philadelphia, PA
Atrial fibrillation (AF) increases the risk for stroke 4- to 5-fold, doubles the risk for dementia, triples the risk for heart failure, and increases the risk for overall mortality by 40% to 90%. AF is also an independent risk factor for stroke recurrence. The National Stroke Association emphasizes the importance of stroke prevention in patients with AF, noting that patients with AF tend to experience more serious strokes than those who do not have AF. Vitamin K antagonists (VKAs) and antiplatelet agents have been mainstays of stroke prevention therapy and have been shown to reduce the risk of stroke by 65% and 22%, respectively. However, the increasing prevalence of AF and its associated morbidity, mortality, diminished quality of life, and high health care costs have spurred development of new therapies for stroke prevention in AF and reduction of AF-related complications.
Cardiologists, internists, and other clinicians play a vital role in improving the management of AF to reduce serious health consequences. This activity will outline risk assessment strategies and examine appropriate anticoagulant options for specific types of patients.
Temple University School of Medicine and MCM Education
Cardiologists, internists, and other clinicians who are involved in the evaluation, diagnosis, and management of patients with atrial fibrillation.
Upon completion of this educational activity, the participant should be able to:
Determine when a patient with AF is at risk for stroke using evidence-based risk scoring assessments.
Identify the major barriers that are causing patients with AF to receive suboptimal anticoagulation.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).
Planning committee members have no financial relationships to disclose.
The information presented in this CME program represents the views and opinions of the individual contributors, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Dr. Arora has no relevant financial relationships with any commercial interests to disclose.
Dr. Blackshear has no relevant financial relationships with any commercial interests to disclose.
Dr. Marchlinski discloses that he has received grant/research support from Biotronic, Medtronic, Boston Scientific, and Biosense Webster. He has served as a consultant for Biotronic, Medtronic, and Boston Scientific. Credit Statements
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Credit Provider Contact Information
School of Medicine
The Albert J. Finestone, MD Office for CME
3500 North Broad Street Philadelphia, PA 19140
Fax: 215-707-8268 Commercial Support Statements
This activity is supported by an independent educational grant from Boehringer Ingelheim.
There are no fees for participating in or receiving credit for this online educational activity.
This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
To access this activity users will need
• A computer with an Internet connection.
• Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser. Certificate Fee
Copyright © 2013. Temple University School of Medicine. All rights reserved.
Presented by Temple University School of Medicine and MCM Education.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, or Boehringer Ingelheim. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To view our privacy policies, please click here.